Santhera Updates Development Strategy for SNT-MC17/idebenone in Friedreich's Ataxia in the US
Revised Clinical and Regulatory Strategy Based on Discussions with FDA Potentially Allows for Accelerated Development Timelines
It is anticipated that both the number of patients needed for the Phase III clinical study and the trial's duration could be significantly reduced, thereby shortening the development timelines approximately by half a year as compared to the Company's previous plans. The positive results of the clinical study conducted in collaboration with the NIH were presented at the 3rd International Friedreich's Ataxia Scientific Conference in Bethesda, Maryland. Specifically, this trial showed improvement of neurological parameters and activities of daily living scores with intermediate and high doses of SNT-MC17/idebenone after six months of treatment in young FRDA patients.
Santhera submitted these data to the FDA in late 2006. In a recent meeting with the Agency, the Company discussed potential amendments to its US clinical development plans for SNT-MC17/idebenone based on these new data. As a result of this meeting, Santhera will file a new protocol under its open IND (Investigational New Drug) within the next few weeks.
According to this protocol, the number of patients involved in the pending Phase III trial will be reduced substantially while the treatment period with SNT-MC17/idebenone will be considerably shortened. The protocol will reflect the major findings from the collaborative clinical trial with the NIH regarding neurological endpoints and the efficacy seen with the intermediate and high dose of SNT-MC17/idebenone. Upon filing the new protocol, Santhera will ask, as recommended by the FDA, for Special Protocol Assessment (SPA) with the Agency which is expected to occur within the next three months. Based on this schedule of events, patient recruitment is expected to start in summer 2007.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.